أرسل هذا في رسالة قصيرة: Preclinical characteristics of the irreversible pan-HER kinase inhibitor neratinib compared with lapatinib : implications for the treatment of HER2-positive and HER2-mutated breast cancer

 _    _     ______    _  _      ___      ______  
| || | ||  /_   _//  | \| ||   / _ \\   /_____// 
| || | ||   -| ||-   |  ' ||  / //\ \\  `____ `  
| \\_/ ||   _| ||_   | .  || |  ___  || /___//   
 \____//   /_____//  |_|\_|| |_||  |_|| `__ `    
  `---`    `-----`   `-` -`  `-`   `-`  /_//     
                                        `-`